© Reuters. FILE PHOTO: A man receives a second dose of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) at the hall three of the Belgrade Fair, in Belgrade, Serbia, April 13, 2021. REUTERS/Marko Djurica
(Reuters) – Pfizer Inc (NYSE:) on Tuesday raised its annual sales forecast for the COVID-19 vaccine it co-developed with Germany’s BioNTech SE (NASDAQ:), as a vaccination drive across the globe intensifies.
The U.S. drugmaker now expects sales of $26 billion from the vaccine in 2021, up from its prior forecast of about $15 billion. The goal assumes that 1.6 billion vaccine doses will be delivered in the year.
Cost and gross profit from the vaccine are split 50-50 between Pfizer and BioNTech.
Pfizer has said it expects to profit from the vaccine, while some drugmakers including Johnson & Johnson (NYSE:) have said their vaccine will be available on a not-for-profit basis until the end of the pandemic.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.